Cantor Fitzgerald Initiates Coverage on Bicycle Therapeutics (NASDAQ:BCYC)

Equities research analysts at Cantor Fitzgerald began coverage on shares of Bicycle Therapeutics (NASDAQ:BCYCGet Rating) in a research note issued on Thursday, FinViz reports. The brokerage set an “overweight” rating and a $80.00 price target on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 70.25% from the stock’s current price.

Several other equities analysts have also recently weighed in on BCYC. Morgan Stanley initiated coverage on shares of Bicycle Therapeutics in a research report on Monday, February 14th. They issued an “equal weight” rating and a $60.00 price target on the stock. JMP Securities dropped their price target on shares of Bicycle Therapeutics from $85.00 to $70.00 and set a “market outperform” rating on the stock in a research report on Thursday, March 3rd. Needham & Company LLC initiated coverage on shares of Bicycle Therapeutics in a research report on Thursday, December 9th. They issued a “buy” rating and a $85.00 price target on the stock. B. Riley dropped their price target on shares of Bicycle Therapeutics from $72.00 to $62.00 in a research report on Wednesday, March 2nd. Finally, SVB Leerink initiated coverage on shares of Bicycle Therapeutics in a research report on Friday, December 17th. They set an “outperform” rating and a $70.00 target price on the stock. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $68.33.

Shares of Bicycle Therapeutics stock opened at $46.99 on Thursday. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.09. The business has a 50-day moving average price of $44.99 and a two-hundred day moving average price of $50.26. Bicycle Therapeutics has a 1-year low of $26.39 and a 1-year high of $62.08.

Bicycle Therapeutics (NASDAQ:BCYCGet Rating) last released its quarterly earnings data on Tuesday, March 1st. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.03). The company had revenue of $3.77 million for the quarter, compared to the consensus estimate of $6.31 million. Bicycle Therapeutics had a negative return on equity of 33.36% and a negative net margin of 571.25%. On average, sell-side analysts forecast that Bicycle Therapeutics will post -3.05 earnings per share for the current year.

Large investors have recently made changes to their positions in the business. Shilanski & Associates Inc. bought a new stake in shares of Bicycle Therapeutics during the 4th quarter worth $314,000. Personal CFO Solutions LLC lifted its holdings in shares of Bicycle Therapeutics by 3.7% during the 3rd quarter. Personal CFO Solutions LLC now owns 7,558 shares of the company’s stock worth $314,000 after acquiring an additional 273 shares during the last quarter. HighMark Wealth Management LLC lifted its holdings in shares of Bicycle Therapeutics by 590.9% during the 4th quarter. HighMark Wealth Management LLC now owns 4,325 shares of the company’s stock worth $263,000 after acquiring an additional 3,699 shares during the last quarter. State of New Jersey Common Pension Fund D bought a new stake in shares of Bicycle Therapeutics during the 3rd quarter worth $203,000. Finally, Jump Financial LLC bought a new stake in shares of Bicycle Therapeutics during the 3rd quarter worth $715,000. 54.69% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile (Get Rating)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

See Also

Analyst Recommendations for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.